rmdopen.bmj5d
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...
rmdopen.bmj5d
Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
Objectives Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are overlapping autoinflammatory diseases affecting people over 50 years. The diseases are treated with immunosuppressive drugs ...
rmdopen.bmj6d
Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive
Objectives Guidelines advise to test for anti–Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) antibodies in all patients with rheumatoid ...
rmdopen.bmj6d
Current Issue
Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis (12 December, 2024) ...
rmdopen.bmj11d
Patient appropriateness for total knee arthroplasty and predicted probability of a good outcome
Objectives One-fifth of total knee arthroplasty (TKA) recipients experience a suboptimal outcome. Incorporation of patients’ preferences in TKA assessment may improve outcomes. We determined the ...
rmdopen.bmj6d
Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis
Objective Non-pharmacological interventions support patients with connective tissue diseases to better cope with and self-manage their diseases. This study aimed to map existing evidence on ...
rmdopen.bmj2d
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remission in patients with early active rheumatoid arthritis (RA). Methods Five-year outcomes were compared ...
rmdopen.bmj5d
Anticoagulation in venous thromboembolism in Behçet’s syndrome: friend or foe?
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
rmdopen.bmj1y
The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?
Inflammatory bowel disease (IBD) associated arthritis is a subgroup of spondyloarthritis (SpA) that has suffered from lack of recognition in rheumatology clinical and research circles for over 100 ...
rmdopen.bmj2mon
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
Objective Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these ...
rmdopen.bmj2mon
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
1 Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands 2 Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands Objectives Although current ...
rmdopen.bmj3mon
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...